Skip to main content

Table 1 Characteristics and behaviors of participants in CTN clinical trials compared to people with opioid use disorder (1) identifying need for treatment [National Survey on Drug use and Health (NSDUH)], (2) entering substance use treatment [Treatment Episodes Dataset (TEDS)], and (3) from rural regions of the U.S. [Rural Opioids Initiative (ROI)]

From: Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations

Characteristic/ behavior

CTN trials

N = 673

 N (%)

NSDUHa

N = 661,650

 N (%)

SMD

TEDS

N = 71,751

 N (%)

SMD

ROI

N = 1933

 N (%)

SMD

Age

  

0.085

 

0.16

 

0.19

 18–29

242 (36.0)

229,715 (34.7)

 

20,430 (28.5)

 

593 (31)

 

 30–49

333 (49.5)

314,933 (47.6)

 

39,559 (55.1)

 

1118 (58.5)

 

 50+

98 (14.6)

117,002 (17.7)

 

11,762 (16.4)

 

199 (10.4)

 

Male sex

465 (69.1)

361,130 (54.6)

0.30

42,805 (59.7)

0.2

1143 (59.1)

0.21

Race/ethnicity

  

0.35

 

0.28

 

0.74

 Non-Hispanic Black/African-American

117 (17.4)

65,584 (9.9)

 

9720 (13.5)

 

56 (2.9)

 

 Non-Hispanic White

425 (63.2)

520,682 (78.7)

 

51,373 (71.6)

 

1591 (82.3)

 

 Hispanic/Latino

109 (16.2)

65,379 (9.9)

 

6452 (9)

 

77 (4)

 

 Other

22 (3.3)

10,004 (1.5)

 

4206 (5.9)

 

209 (10.8)

 

Education

  

0.26

 

0.36

 

0.35

 < High school

171 (25.9)

108,560 (16.4)

 

17,366 (25.3)

 

437 (22.6)

 

 High school diploma/GED

225 (34.1)

229,536 (34.7)

 

34,031 (49.5)

 

945 (48.9)

 

 Some college

220 (32.4)

256,390 (38.8)

 

14,152 (20.6)

 

507 (26.3)

 

 Bachelor’s or higher

43 (6.5)

67,164 (10.2)

 

3187 (4.6)

 

42 (2.2)

 

Employed

190 (24.6)

284,520 (43)

0.40

18,563 (22)

0.06

765 (39.6)

0.32

Homeless

185 (27.5)

N/A

 

7532 (11b)

0.43

1015 (53.3b)

0.55

Depression history

230 (34.2)

286,791 (44.0b)

0.20

 N/A

 

N/A

 

Heavy alcohol use

73 (10.8)

77,006 (11.6)

0.025

5876 (8.2)

0.09

240 (12.4)

0.05

Heavy benzodiazepine use

65 (9.7)

105,825 (16)

0.19

5869 (8.2)

0.05

156 (8.1)

0.06

 Injection drug use

443 (65.5)

240,535 (36.4)

0.63

38,839 (54.1)

0.26

1851 (95.8)

0.81

Average SMD

  

0.27

 

0.21

 

0.36

  1. CTN National Drug Abuse Treatment Clinical Trials Network, NSDUH National Survey on Drug Use and Health, TEDS Treatment Episodes Dataset, ROI Rural Opioids Initiative, SMD standardized mean difference
  2. aWeighted N (%). Actual N = 139
  3. bDenominator excludes missing data in depression and homelessness variables